Needham analyst Joseph Stringer maintained a Buy rating on Ionis Pharmaceuticals today and set a price target of $55.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Joseph Stringer has given his Buy rating due to a combination of factors including Ionis Pharmaceuticals’ strong financial performance and promising future prospects. The company reported second-quarter 2025 revenues of $452 million, significantly surpassing both the analyst’s expectations and the consensus estimate. This impressive revenue was largely driven by a substantial upfront payment from a deal with Ono for sapablursen, as well as better-than-expected performance from their product Tryngolza.
Additionally, the anticipation of pivotal Phase 3 data for olezarsen in September is expected to be a major catalyst for the stock. Joseph Stringer expresses a positive bias towards the outcome of this readout, which could further enhance the company’s market position. These factors collectively underpin the Buy rating, reflecting confidence in both the current financial health and the future growth potential of Ionis Pharmaceuticals.
Stringer covers the Healthcare sector, focusing on stocks such as Cidara Therapeutics, Gilead Sciences, and Vir Biotechnology. According to TipRanks, Stringer has an average return of 5.5% and a 41.69% success rate on recommended stocks.
In another report released yesterday, TD Cowen also reiterated a Buy rating on the stock with a $59.00 price target.